Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Pfizer has agreed to pay up to $250mn to settle more than 10,000 US lawsuits over cancer risks associated ...
GSK (NYSE:GSK) said it has started to appeal a recent court ruling in Delaware that allowed tens of thousands of lawsuits to ...
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to pay up to $250 million. What Happened: The settlement, disclosed in a ...
Along with GSK and Pfizer, Sanofi and Boehringer Ingelheim GmbH have been sued by consumers. After the federal cases were ...
Zantac hit the US market as a prescription drug in 1983 before transforming into an over-the-counter heartburn treatment in ...
GSK and other drugmakers on Monday asked a Delaware court for permission to appeal a ruling allowing more than 70,000 ...
The decision of a Delaware judge on Friday to allow more than 75,000 Zantac lawsuits to go forward to jury trials has left ...
A woman who claimed in a lawsuit that GSK’s discontinued heartburn drug Zantac caused her breast cancer dropped her case ...
GSK’s shares fell sharply following a judge's decision to allow more than 70,000 lawsuits to proceed, alleging it’s Zantac ...
A woman who claimed in a lawsuit that GSK's discontinued heartburn drug Zantac caused her breast cancer dropped her case shortly before it was set to go to trial in Illinois state court on Monday, the ...
A look at similar cases might suggest this latest ruling could cost GSK tens of billions of dollars in potential liabilities.